Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

March 10, 2026

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
March 3, 2026

Immunic to Participate in Investor Conferences in March
February 26, 2026

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
February 17, 2026

Immunic Announces Closing of Oversubscribed Private Placement Financing
February 13, 2026

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
February 4, 2026

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
January 7, 2026

Immunic Highlights 2025 Accomplishments and Upcoming Milestones
November 26, 2025

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
November 13, 2025

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 29, 2025

Immunic to Participate in Industry and Investor Conferences in November

Show per page